Stoke Therapeutics, Inc.
STOKStoke Therapeutics is a late-stage clinical biotechnology company focused on treating severe genetic diseases by upregulating protein expression using RNA-based medicines.
Earnings
Next report
Aug 11, 2026 (in a month)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Stoke Therapeutics is a late-stage clinical biotechnology company focused on treating severe genetic diseases by upregulating protein expression using RNA-based medicines. The company utilizes its proprietary TANGO platform to develop antisense oligonucleotides that restore functional protein levels in patients with haploinsufficiencies, where one gene copy is mutated. Their lead programs target life-altering conditions of the central nervous system and the eye.
A pioneer in developing disease-modifying therapies for haploinsufficiencies using a proprietary RNA-based upregulation platform (TANGO).
Questions, answered.
- What is Stoke Therapeutics, Inc.'s market cap?
- Stoke Therapeutics, Inc. (STOK) has a market capitalization of $2.0B and trades on NASDAQ.
- What is Stoke Therapeutics, Inc.'s revenue and profitability?
- Stoke Therapeutics, Inc. generated $32.1M in trailing twelve-month revenue with a net loss of $169.8M, representing a net margin of -529.2%, with free cash flow of $25.8M. These figures are based on the Q1 2026 filing.
- Who are Stoke Therapeutics, Inc.'s competitors?
- Stoke Therapeutics, Inc.'s key competitors include Ionis Pharmaceuticals, Jazz Pharmaceuticals, Xenon Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Stoke Therapeutics, Inc. partner with?
- Stoke Therapeutics, Inc.'s notable partners include Biogen, Acadia Pharmaceuticals Inc., University of Southampton.
- Where is Stoke Therapeutics, Inc. headquartered?
- Stoke Therapeutics, Inc. is headquartered in United States of America and employs approximately 110 people. It has been publicly traded since 2019.
